FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016146576> ?p ?o ?g. }

• W3016146576 endingPage "4539" @default.
• W3016146576 startingPage "4539" @default.
• W3016146576 abstract "4539 Background: The Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC) trial reported an acceptable safety profile for neoadjuvant Xelox +/- AZD8931 but limited efficacy. We utilized EAC patient samples from DEBIOC to evaluate the impact of neoadjuvant Xelox +/-AZD8931 on biological pathways using a unique software driven solution. Methods: 24 pre-treatment FFPE EAC biopsies and 17 matched surgical resection specimens were transcriptionally profiled using the Almac Diagnostics Xcel Array. Gene expression data was analyzed using the Almac clara T total mRNA report V3.0.0, reporting on 92 gene expression signatures and 7337 single genes associated with 10 key biologies. Paired Wilcoxon tests (5% significance level) were used to evaluate changes in clara T scores pre- and post-treatment. EGFR and Her2 expression were assessed by IHC and FISH. Results: 15 patients received Xelox+AZD8931 and 9 Xelox alone. Hierarchical clustering of biopsies identified 4 major clusters: Inflammation active, Genomic Instability active, EGFR & MAPK active, and EMT & Angiogenesis active. Comparison of signature scores pre- and post- neoadjuvant treatment demonstrated a significant reduction in scores relating to DNA damage repair (DDR) deficiency (Almac DNA Damage assay, p< 0.0001; BRCAness Profile, p= 0.0025; HRD Gene Signature, p< 0.0001; BRCA1ness Signature, p= 0.0004) and a significant increase in angiogenesis signatures (Almac Angiogenesis Assay, p= 0.0002; Angio Predictive G model, p= 0.0228; Angiogenesis Signature A, p= 0.0034) and EMT signatures (EMT Signature, p= 0.0031, EMT Enrichment Score, p= 0.0013, Pan-Can EMT Signature B, p= 0.0001). Comparing pre- and post-treatment signature scores in patients treated with Xelox +/-AZD8931 revealed a significant reduction in EGFR Sensitivity Signature ( p= 0.0088), ERBB2-specific Gene Expression Signature ( p= 0.0127) and Hallmark PI3K-AKT-MTOR Signaling ( p= 0.0195) in those treated with Xelox + AZD8931 in keeping with the mechanism of action of AZD8931. Downregulation of AKT signaling was confirmed in AZD8931 treated and resistant cell lines. Conclusions: We report the use of a novel software tool to apply 92 gene expression signatures to EAC biopsy and resection specimens from the DEBIOC trial to provide insight into mechanisms of action. Neoadjuvant treatment was associated with a reduction in DDR deficiency and an increase in angiogenesis and EMT signatures whilst a reduction in EGFR, Her2 and AKT pathways was noted with AZD8931 treatment." @default.
• W3016146576 created "2020-04-17" @default.
• W3016146576 creator A5002597498 @default.
• W3016146576 creator A5005391044 @default.
• W3016146576 creator A5007749485 @default.
• W3016146576 creator A5017147519 @default.
• W3016146576 creator A5028305538 @default.
• W3016146576 creator A5030753008 @default.
• W3016146576 creator A5031332590 @default.
• W3016146576 creator A5031661937 @default.
• W3016146576 creator A5031840599 @default.
• W3016146576 creator A5040705743 @default.
• W3016146576 creator A5045865889 @default.
• W3016146576 creator A5050812459 @default.
• W3016146576 creator A5051430596 @default.
• W3016146576 creator A5054312745 @default.
• W3016146576 creator A5062408400 @default.
• W3016146576 creator A5064851637 @default.
• W3016146576 creator A5070327049 @default.
• W3016146576 creator A5080214836 @default.
• W3016146576 creator A5088266020 @default.
• W3016146576 date "2020-05-20" @default.
• W3016146576 modified "2023-10-14" @default.
• W3016146576 title "Translational analysis of esophageal adenocarcinoma (EAC) patients treated with oxaliplatin and capecitabine (Xelox) +/- the dual ErbB inhibitor AZD8931 in the DEBIOC study." @default.
• W3016146576 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.4539" @default.
• W3016146576 hasPublicationYear "2020" @default.
• W3016146576 type Work @default.
• W3016146576 sameAs 3016146576 @default.
• W3016146576 citedByCount "0" @default.
• W3016146576 crossrefType "journal-article" @default.
• W3016146576 hasAuthorship W3016146576A5002597498 @default.
• W3016146576 hasAuthorship W3016146576A5005391044 @default.
• W3016146576 hasAuthorship W3016146576A5007749485 @default.
• W3016146576 hasAuthorship W3016146576A5017147519 @default.
• W3016146576 hasAuthorship W3016146576A5028305538 @default.
• W3016146576 hasAuthorship W3016146576A5030753008 @default.
• W3016146576 hasAuthorship W3016146576A5031332590 @default.
• W3016146576 hasAuthorship W3016146576A5031661937 @default.
• W3016146576 hasAuthorship W3016146576A5031840599 @default.
• W3016146576 hasAuthorship W3016146576A5040705743 @default.
• W3016146576 hasAuthorship W3016146576A5045865889 @default.
• W3016146576 hasAuthorship W3016146576A5050812459 @default.
• W3016146576 hasAuthorship W3016146576A5051430596 @default.
• W3016146576 hasAuthorship W3016146576A5054312745 @default.
• W3016146576 hasAuthorship W3016146576A5062408400 @default.
• W3016146576 hasAuthorship W3016146576A5064851637 @default.
• W3016146576 hasAuthorship W3016146576A5070327049 @default.
• W3016146576 hasAuthorship W3016146576A5080214836 @default.
• W3016146576 hasAuthorship W3016146576A5088266020 @default.
• W3016146576 hasBestOaLocation W30161465762 @default.
• W3016146576 hasConcept C104317684 @default.
• W3016146576 hasConcept C121608353 @default.
• W3016146576 hasConcept C126322002 @default.
• W3016146576 hasConcept C143998085 @default.
• W3016146576 hasConcept C150194340 @default.
• W3016146576 hasConcept C2777909004 @default.
• W3016146576 hasConcept C2778292576 @default.
• W3016146576 hasConcept C2779733811 @default.
• W3016146576 hasConcept C2780394083 @default.
• W3016146576 hasConcept C2780962732 @default.
• W3016146576 hasConcept C502942594 @default.
• W3016146576 hasConcept C526805850 @default.
• W3016146576 hasConcept C530470458 @default.
• W3016146576 hasConcept C55493867 @default.
• W3016146576 hasConcept C71924100 @default.
• W3016146576 hasConcept C86803240 @default.
• W3016146576 hasConceptScore W3016146576C104317684 @default.
• W3016146576 hasConceptScore W3016146576C121608353 @default.
• W3016146576 hasConceptScore W3016146576C126322002 @default.
• W3016146576 hasConceptScore W3016146576C143998085 @default.
• W3016146576 hasConceptScore W3016146576C150194340 @default.
• W3016146576 hasConceptScore W3016146576C2777909004 @default.
• W3016146576 hasConceptScore W3016146576C2778292576 @default.
• W3016146576 hasConceptScore W3016146576C2779733811 @default.
• W3016146576 hasConceptScore W3016146576C2780394083 @default.
• W3016146576 hasConceptScore W3016146576C2780962732 @default.
• W3016146576 hasConceptScore W3016146576C502942594 @default.
• W3016146576 hasConceptScore W3016146576C526805850 @default.
• W3016146576 hasConceptScore W3016146576C530470458 @default.
• W3016146576 hasConceptScore W3016146576C55493867 @default.
• W3016146576 hasConceptScore W3016146576C71924100 @default.
• W3016146576 hasConceptScore W3016146576C86803240 @default.
• W3016146576 hasIssue "15_suppl" @default.
• W3016146576 hasLocation W30161465761 @default.
• W3016146576 hasLocation W30161465762 @default.
• W3016146576 hasOpenAccess W3016146576 @default.
• W3016146576 hasPrimaryLocation W30161465761 @default.
• W3016146576 hasRelatedWork W1997133872 @default.
• W3016146576 hasRelatedWork W2075077394 @default.
• W3016146576 hasRelatedWork W2077919698 @default.
• W3016146576 hasRelatedWork W2267469086 @default.
• W3016146576 hasRelatedWork W2321520688 @default.
• W3016146576 hasRelatedWork W2999149094 @default.
• W3016146576 hasRelatedWork W3006318744 @default.
• W3016146576 hasRelatedWork W3015158350 @default.
• W3016146576 hasRelatedWork W3040700866 @default.
• W3016146576 hasRelatedWork W3055760424 @default.
• W3016146576 hasVolume "38" @default.

• next